AuthorCitation

Faculty Opinions recommendation of A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 3, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.737855899.793579682

Faculty Opinions recommendation of Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 3, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.737229277.793579681

Faculty Opinions recommendation of Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 3, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734871049.793579680

Faculty Opinions recommendation of Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.736202756.793579679

Faculty Opinions recommendation of Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734432600.793579678

Faculty Opinions recommendation of A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 2, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735081004.793579677

Faculty Opinions recommendation of Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.736346370.793579676

Faculty Opinions recommendation of TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735806594.793579674

Faculty Opinions recommendation of Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 30, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732610815.793579673

Faculty Opinions recommendation of Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 29, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734986288.793579672

Borad, Mitesh J.

Citations 336

Faculty Opinions recommendation of A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.

Faculty Opinions recommendation of Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.

Faculty Opinions recommendation of Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.

Faculty Opinions recommendation of Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Faculty Opinions recommendation of Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

Faculty Opinions recommendation of A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations.

Faculty Opinions recommendation of Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.

Faculty Opinions recommendation of TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.

Faculty Opinions recommendation of Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.

Faculty Opinions recommendation of Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.